A
Alan R. Zinsmeister
Researcher at Mayo Clinic
Publications - 542
Citations - 56210
Alan R. Zinsmeister is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Population & Gastric emptying. The author has an hindex of 118, co-authored 542 publications receiving 52909 citations. Previous affiliations of Alan R. Zinsmeister include University of Rochester & University of Southern California.
Papers
More filters
Journal ArticleDOI
Non-enteric infections, antibiotic use, and risk of development of functional gastrointestinal disorders
H. Paula,Madhusudan Grover,Smita Halder,Giles R. Locke,Cathy D. Schleck,Alan R. Zinsmeister,Nicholas J. Talley,Nicholas J. Talley +7 more
TL;DR: This work investigated whether non‐enteric infections and antibiotic exposure are also associated with the development of functional gastrointestinal disorders (FGIDs) and found no clear link between these factors and IBS.
Journal ArticleDOI
Effect of the NK(3) receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans.
Lesley A. Houghton,Filippo Cremonini,Michael Camilleri,Irene Busciglio,Catherine Fell,V. Cox,David H. Alpers,O. E. Dewit,George E. Dukes,E. Gray,Richard Lea,Alan R. Zinsmeister,Peter J. Whorwell +12 more
TL;DR: At the doses tested, talnetant has no effect on rectal compliance or distension‐induced rectal sensation in healthy participants, and results obtained at the two centres differed minimally, with intensity scores at one centre consistently somewhat lower.
Journal ArticleDOI
The effect of short‐term, low‐dose tricyclic and tetracyclic antidepressant treatment on satiation, postnutrient load gastrointestinal symptoms and gastric emptying: a double‐blind, randomized, placebo‐controlled trial
TL;DR: Tricyclic and tetracyclic antidepressant agents do not appear to have significant effects on gastric motor or satiation postnutrient challenge in healthy individuals at the doses tested.
Journal ArticleDOI
Adalimumab for Crohn's disease in clinical practice at Mayo clinic: The first 118 patients
Jason M. Swoger,Edward V. Loftus,William J. Tremaine,William A. Faubion,Darrell S. Pardi,Sunanda V. Kane,Karen A. Hanson,W. Scott Harmsen,Alan R. Zinsmeister,William J. Sandborn +9 more
TL;DR: Adalimumab was both effective and well tolerated for the treatment of CD in this tertiary practice with a high prevalence of past infliximab exposure, and largely predates FDA approval of adalimumabs for CD.
Journal ArticleDOI
A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults.
April Grudell,Seth Sweetser,Michael Camilleri,Deborah J. Eckert,Maria I. Vazquez-Roque,Paula Carlson,Duane Burton,Autumn E. Braddock,Matthew M. Clark,Karen M. Graszer,Sarah A. Kalsy,Alan R. Zinsmeister +11 more
TL;DR: Patient selection based on candidate genes may enhance response to multidimensional sibutramine and behavioral therapy for obesity.